DPP4 and type 2 diabetes mellitus: However, another NMA of 301 clinical trials found that there were no significant differences in the associations between any of nine available classes of ADM alone or in combination (metformin, sulfonylurea, thiazolidinediones, DPP-4 inhibitor, SGLT-2 inhibitor, basal insulin, basal-bolus insulin, α-glucosidase inhibitor, GLP-1 receptor agonist) and the risk of cardiovascular or all-cause mortality among patients with T2D [12].